BioCardia, Inc.

BCDA

US09060U6064

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-07 EDT			5-day change	1st Jan Change
3.72 ^USD	-14.78%		-19.48%	-62.66%

06-07	BioCardia Receives Patent for Transendocardial Biotherapeutic Delivery Catheter; Shares Rise Pre-Bell	MT
05-21	BioCardia to Implement 1-for-15 Reverse Stock Split; Shares Fall After Hours	MT

BioCardia, Inc. Announces Resignation of Richard Thomas Allen, Vice President of Quality, Effective August 17, 2018

August 16, 2018 at 06:11 am

Richard Thomas Allen, the Vice President of Quality of BioCardia, Inc. has resigned from the Company effective August 17, 2018.

Latest news about BioCardia, Inc.

BioCardia Receives Patent for Transendocardial Biotherapeutic Delivery Catheter; Shares Rise Pre-Bell	06-07	MT
BioCardia to Implement 1-for-15 Reverse Stock Split; Shares Fall After Hours	05-21	MT
Transcript : BioCardia, Inc., Q1 2024 Earnings Call, May 14, 2024	05-14
BioCardia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial	05-01	CI
Transcript : BioCardia, Inc. - Special Call	04-30
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	04-25	CI
Transcript : BioCardia, Inc., 2023 Earnings Call, Mar 27, 2024	03-27
BioCardia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
BioCardia, Inc. and StemCardia, Inc. Announce Long-Term Partnership to Advance StemCardia?s Investigational Pluripotent Stem Cell Product Candidate for Treatment of Heart Failure	03-13	CI
BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	03-12	CI
Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	03-04	CI
BioCardia, Inc. announced that it expects to receive $0.874999 million in funding	02-08	CI
BioCardia, Inc. Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA	02-08	CI
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction	12-19	CI
BioCardia, Inc. Announces Expected Cardiamp Heart Failure Japan Approval Based on Pharmaceutical and Medical Device Agency Consultation Minutes	12-18	CI
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure	11-29	CI
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon	11-16	MT
Sector Update: Health Care	11-16	MT
BioCardia to Sell $1.3 Million Shares to Healthcare Investor; Shares Fall	11-16	MT
Sector Update: Health Care Stocks Higher Late Afternoon	11-14	MT
Top Midday Gainers	11-14	MT
Sector Update: Health Care Stocks Advancing in Afternoon Trading	11-14	MT
Sector Update: Health Care	11-14	MT
BioCardia Climbs Amid FDA Approval for Phase 3 Trial of CardiAMP Cell Therapy for Ischemic Heart Failure	11-14	MT

BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
BIOCARDIA, INC.	-62.66%	6.79M
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.21B
ARGENX SE	+0.87%	22.78B
GENMAB A/S	-10.74%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.31%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B

Bio Therapeutic Drugs

BioCardia, Inc.

Equities

BCDA

US09060U6064

Biotechnology & Medical Research

BioCardia, Inc. Announces Resignation of Richard Thomas Allen, Vice President of Quality, Effective August 17, 2018

Latest news about BioCardia, Inc.

Chart BioCardia, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs